Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Covaxin is not approved in the USA for any age group
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Subscribe To Our Newsletter & Stay Updated
